Swiss Re Updates Life Guide to Address Longevity Drugs

On August 11, 2025, Swiss Re announced an update to its Life Guide, incorporating guidance on the emerging use of repurposed longevity drugs like metformin and rapamycin. Originally developed for type 2 diabetes and organ transplant recipients, these drugs are now popular for their potential anti-aging effects. However, the long-term impacts remain uncertain.

This update aids insurance underwriters in evaluating applications involving these medications, particularly those self-prescribed. The Life Guide, utilized by over 800 insurers in more than 100 countries, supports evidence-based decisions amid evolving health risks.

Natalie Kelly of Swiss Re emphasized the toolkit's importance in addressing developing risks. As drugs like rapamycin pose potential immunosuppressive risks, the updated guide offers clear protocols for underwriters.